Conveying the Implications of U=U for People Newly Diagnosed With HIV

Release Date September 13, 2024
Expiration Date September 13, 2025
Format Webcast
CME 0.25 credits
CE 0.25 contact hours
Top Continue Button Placeholder

Acknowledgement

This activity is provided by Talem Health and RME Collaborative.
     





In collaboration with the Southeast AIDS Education & Training Center.




This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Credit Available

  • Physicians — maximum of 0.25 AMA PRA Category 1 Credit
  • Nurses — 0.25 Contact Hour
  • Pharmacists — 0.25 Contact Hour (0.025 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, and pharmacists who care for patients from rural and underserved areas. 

Program Overview

Delivering the diagnosis of HIV is a pivotal moment in the patient-clinician relationship. This video, which is part of the CME/CE series entitled Optimizing Outcomes for Patients With HIV: Best Practices for Patient-Centered Conversations, demonstrates how to discuss the concept of U=U (undetectable = untransmissible) with a newly diagnosed Black ciswoman considering pregnancy. The scenario emphasizes the importance of building trust, encouraging adherence to therapy, and addressing patient concerns about viral suppression and stigma. Strategies for involving patients in their treatment decisions and alleviating anxiety about transmission to partners and during pregnancy are also highlighted.

The content for this enduring activity was recorded in August 2024.

Learning Objective

Upon completion of this activity, participants should be better able to: 

  • Employ effective communication methods to foster open patient-clinician communication and reduce HIV-related stigma

Faculty

Onyema E. Ogbuagu, MD, FACP, FIDSA
Associate Professor of Medicine
Director, Antivirals and Vaccines Research Program
Yale School of Medicine
Attending Physician, Infectious Diseases
Yale-New Haven Health, Yale Medicine
New Haven, CT
 

Tiye Link, EdD, MS, MBA, MDIV
Program Director, Healthy University
Peer Educator
Nashville CARES
Nashville, TN

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 0.25 contact hour (0.025 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-019-H02-P)
Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Onyema E. Ogbuagu, MD, FACP, FIDSA, has disclosed the following relevant financial relationships: consultant/advisory board member for Gilead Sciences, Inc., Janssen Pharmaceuticals, and ViiV Healthcare; speakers’ bureau member for Gilead Sciences, Inc.

Tiye Link, EdD, MS, MBA, MDIV, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

  1. Read the CME/CE information, including learning objectives and disclosure statements.
  2. Complete the pre-test.
  3. View the online activity.
  4. Complete the post-test and evaluation form.

A post-test score of 100% is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com